Belluscura Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
22
- Latest Deal Type
-
PIPE
- (Announced)
- Latest Deal Amount
-
$4.69M
- Investors
-
2
Belluscura General Information
Description
Belluscura PLC is a medical device company. Its first product, the X-PLOR, is a lightweight FDA-cleared portable oxygen concentrator designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices. The company has only one operating segment being the sale of oxygen concentrators in the United States. The X-PLO2R weighs less than 1.5kg (3.25 lbs) and it is the first modular portable oxygen concentrator it will generate more oxygen by weight than any other FDA-cleared POC in its class. It either owns or exclusively licenses a total of 26 patents and applications relating to oxygen enrichment devices and treatments.
Contact Information
Website
belluscurahealth.comCorporate Office
- 15 Fetter Lane
- London EC1M 4JN
- England, United Kingdom
Corporate Office
- 15 Fetter Lane
- London EC1M 4JN
- England, United Kingdom
Belluscura Timeline
Belluscura Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 15. PIPE | 06-Feb-2025 | $4.69M | Announced | Generating Revenue | ||
| 14. 2PO | 11-Feb-2025 | Completed | Generating Revenue | |||
| 13. PIPE | 02-Jul-2024 | Completed | Generating Revenue | |||
| 12. PIPE | 31-May-2023 | Completed | Generating Revenue | |||
| 11. PIPE | 10-Feb-2023 | Completed | Generating Revenue | |||
| 10. IPO | 28-May-2021 | Completed | Generating Revenue | |||
| 9. Secondary Transaction - Private | 01-Mar-2021 | Completed | Generating Revenue | |||
| 8. Early Stage VC | 10-Jun-2020 | Completed | Generating Revenue | |||
| 7. Early Stage VC | 31-Oct-2019 | $2.91M | $10.2M | Completed | Generating Revenue | |
| 6. Early Stage VC | 04-Dec-2018 | $3.53M | $7.26M | Completed | Generating Revenue |
Belluscura Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 1,117,918 | $0.012352 | $0.62 | $0.62 | $0.62 | 2.56% | ||
| Ordinary | 2,500,000 | $0.012352 | $0.52 | $0.52 | $0.52 | 5.73% |
Belluscura Comparisons
Industry
Financing
Details
Belluscura Competitors (3)
One of Belluscura’s 3 competitors is Inogen, a Formerly VC-backed company based in Beverly, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Inogen | Formerly VC-backed | Beverly, MA | ||||
| CAIRE (Georgia) | Formerly VC-backed | Ball Ground, GA | ||||
| Philips | Corporation | Amsterdam, Netherlands |
Belluscura Patents
Belluscura Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4117758-B1 | Oxygen delivery system for the treatment of chronic obstructive pulmonary disease | Active | 13-Mar-2020 | ||
| AU-2021233029-A1 | Portable ventilator | Active | 13-Mar-2020 | ||
| AU-2021233029-B2 | Portable ventilator | Inactive | 13-Mar-2020 | ||
| EP-4117758-A1 | Portable ventilator | Active | 13-Mar-2020 | ||
| EP-4117758-A4 | Portable ventilator | Active | 13-Mar-2020 | A61M16/0672 |
Belluscura Signals
Belluscura Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Tekcapital | Venture Capital | Minority | ||
| Cardiff University | University | Minority |
Belluscura Acquisitions (3)
Belluscura’s most recent deal was a Merger/Acquisition with TMT Acquisition (Special Purpose Acquisition Company (SPAC)) for . The deal was made on 08-Mar-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| TMT Acquisition (Special Purpose Acquisition Company (SPAC)) | 08-Mar-2024 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) | ||
| Nanotether Discovery Science | 25-Apr-2017 | Merger/Acquisition | Discovery Tools (Healthcare) | ||
| Stryker Corporation (Medical Devices) | 13-Apr-2016 | Merger/Acquisition | Other Commercial Services |
Belluscura ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Healthcare
Industry
Rank
Percentile
Medical Devices
Subindustry
Rank
Percentile
Belluscura Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| TMT Acquisition (Special Purpose Acquisition Company (SPAC)) | London, United Kingdom | 2021 |
Belluscura FAQs
-
When was Belluscura founded?
Belluscura was founded in 2015.
-
Where is Belluscura headquartered?
Belluscura is headquartered in London, United Kingdom.
-
What is the size of Belluscura?
Belluscura has 22 total employees.
-
What industry is Belluscura in?
Belluscura’s primary industry is Therapeutic Devices.
-
Is Belluscura a private or public company?
Belluscura is a Private company.
-
What is Belluscura’s current revenue?
The current revenue for Belluscura is .
-
How much funding has Belluscura raised over time?
Belluscura has raised $47.2M.
-
Who are Belluscura’s investors?
Tekcapital and Cardiff University have invested in Belluscura.
-
Who are Belluscura’s competitors?
Inogen, CAIRE (Georgia), and Philips are competitors of Belluscura.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process